AbbVie & Eisai's Humira (adalimumab) Receives Approval for Hidradenitis Suppurativa in Japan
Shots:
- The approval is based on Japanese P-III study results assessing Humira (adalimumab) in patients with moderate-to-severe HS- evaluating its efficacy and safety
- The study resulted in meeting its 1EPs as HiSCR @12 wks. in 13/15 patients- ADRs in 6/15
- Humira (adalimumab) is an anti-TNF-α mAb approved in Japan for rheumatoid arthritis (RA)- plaque psoriasis- arthritic psoriasis- pustular psoriasis- ankylosing spondylitis
Ref: Eisai Co | Image: AbbVie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com